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Abstract. 
Olfactory neuroblastoma is a rare intranasal tumor, and the standard treatment for this dis-
ease remains controversial. Some clinicians contend that a combination of surgery and radio-
therapy is the most efficacious approach, which frequently has a good prognosis. Chemotherapy 
is often reserved for those patients with tumor recurrence and distant metastasis. Regarding 
such metastasis, it is well-known that cervical metastasis indicates poor prognosis. We present-
ed a 36-year-old woman who was diagnosed with a neuroblastoma with neck lymph node me-
tastasis who did not undergo surgery. We treated her with chemotherapy followed by concurrent 
chemoradiation, and the result showed good response without sequela. We also reviewed the 
literature regarding the chemotherapy of olfactory neuroblastoma. In conclusion, olfactory 
neuroblastoma is highly sensitive to chemotherapy. However, long-term surveillanceof patients 
should be maintained in the event of local recurrence and distant metastasis. 
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病例報告  
使用化學治療合併放射線治療於嗅神經母細胞瘤 
楊舜如 1 吳沅樺 2 顏家瑞 1* 
1國立成功大學醫學院附設醫院 內科部血液腫瘤科 
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中文摘要 
  嗅神經母細胞瘤唯一罕見之鼻腔惡性腫瘤，目前尚未有嗅神經母細胞瘤的標準治療
方法。目前最佳的方式為手術治療合併放射線治療，整體而言是為一預後良好之腫瘤，
化學治療則使用於疾病復發或轉移。但若發生頸部淋巴結轉移則為不良預後因子。我們
報告了一名 36 歲女性診斷為嗅神經母細胞瘤合併頸部淋巴結轉移，因考慮外觀而未接受
手術治療。我們使用化學治療，合併放射線治療。腫瘤反應極好，並且未留下相關後遺
症。我們同時回顧了嗅神經母細胞瘤的相關文獻，探討化學治療在嗅神經母細胞瘤之角
色及治療反應，嗅神經母細胞瘤雖然對化療敏感，但仍需長期追蹤。 
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INTRODUCTION 
Olfactory neuroblastoma (ONB), also known as 
esthesioneuroblastoma (ENB), is a rare tumor of the 
nasal cavity. Its incidence is only about 3% of all in-
tranasal tumors [1]. Such tumors are neuroectodermal 
in origin, and arise from the olfactory epithelium. 
ONB is a locallyadvanced malignancy that frequently 
invadesthe skull base and orbit, with an incidence of 
metastases approximating 10 - 33% at the time of di-
agnosis. However, the most common metastaticsiteis-
cervical lymph nodes. In an attempt to better under-
stand and manage this disease, several staging systems 
have been published for ONB. In addition to the TNM 
staging system, the Kadishsystem [2] ismost com-
monly used by clinicians to assess and generate strat-
egies for treatment (Table 1). Although there are dif-
ferent treatments available, the optimal treatment for 
patients with olfactory neuroblastoma has not been 
sufficiently established. Generally, the first line treat-
ment of ONB is surgery, followed by radiotherapy if 
needed [3-5,7]. Chemotherapy is typically used in ne-
oadjuvant treatment, recurrence or distant metastases. 
Here, we present the case of a patient with ONB with 
lymph node metastasis, who was treated with chemo-
therapy followed by concurrent chemoradiation.  
 
CASE REPORT 
A 36-year-old woman suffered from frequent epi-
staxis, which first appeared in 2012.Thereafter, she 
suffered from left exophthalmos and left neck masses 
in early 2013. A cranial MRI was arranged on May 2nd, 
2013 at another hospital, and those images showed 
tumors in the ethmoid sinus and left orbit (Figure 1A). 
There were also abnormal lymph nodes at the left ret-
ropharyngeal space and the left neck (Figure 1B). Also, 
a dumbbell-shaped mass extending across the cribri-
form plate could be observed using a sagittal view 
(Figure 1C). The patient then underwent an ethmoid 
sinus tumor biopsy, where the histological analysis 
indicated the presence of neoplastic small blue round 
cells. Additional testing by immunohistochemical (IHC) 
analysis indicated positive for synaptophysin, negative 
for cytokeratin, common leukocyte antigen, neuron- 
specific enolase (NSE), and chromogranin. Taking 
into consideration the patient’s clinical presentation, 
image study, and pathological result, olfactory neuro-
blastoma, a preliminary diagnosis of Kadish stage C 
was made. Thereafter, the patient was referred to our 
hospital. 
After we undertook a multidisciplinary discussion 
relating to advanced olfactory neuroblastoma, it was 
decided that chemotherapy would be the first line of 
treatment. In May, 2013, the patient started chemo-
therapy using vincristine, doxorubicin, and ifosfamide 
(VAI: vincristine 1.4 mg/m2, max 2 mg, d1, doxorubi-
cin 20 mg/m2 d1-3, ifosfamide 2,000 mg/m2 d1-3) 
every 21-day cycle. Significant improvement of the 
exophthalmos was observed after the first chemother-
apeutic cycle had been completed. Treatment toxicity 
included grade 1 nausea and grade 3 neutropenia. Ad-
ditionally, G-CSF was followed by chemotherapy 
subsequent to cycle 2. Then, we performed an addi-
tional MRI after two cycles of chemotherapy. The 
MRI showed partial response to the treatment, with 
left ethmoid sinus residual tumor and left neck small 
lymph nodes (Figure 2A, 2B). We thereafter arranged 
concurrent chemoradiationtherapy, applying 5000 cGy  
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Table 1. Kadish staging system 
Stage A Tumor confined to the nasal cavity 
Stage B Tumor confined to the nasal cavity and 
paranasal sinuses 
Stage C The tumor extends beyond the nasal cavity 
and paranasal sinuses 
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Figure 1. (A) There is an irregular tumor in the eth-
moid sinus with left lamina papyracea and 
orbit involvement on Gd-enhanced T1 
weighted image. (B) Enlarged lymph nodes 
are at the left neck level II, III, IV areas. (C) 
A dumbbell-shaped mass (outlined in white) 
extending across the cribriform plate 
 
 
 
 
 
 
over the left neck regional lymph nodes and 6000 cGy 
for pre-chemotherapy tumor bed (left ethmoid, frontal, 
maxillary and spenoid sinus). A follow-up MRI in 
December 2013 showed regressed ethmoid sinus tu-
mor and no abnormal neck lymph node (Figure 3A, 
3B). There were no sequelae after treatment. 
 
DISCUSSION 
Olfactory neuroblastoma is a rarely-occurring tu-
mor. Several approaches to the treatment of advanced 
ONB have been postulated to increase overall and 
recurrence-free survival. In our case, routine work-up 
testing revealed pathologic findings of small blue 
round cells (Figure 4A). The differential diagnosis of 
small blue round cells originating from the sinonasal 
tract includes squamous cell carcinoma, undifferenti-
ated carcinoma, ONB, neuroendocrine tumor, and 
lymphoma. However, there were no features of carci- 
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Figure 2. (A) The post contrast T1 weighted image shows smaller enhanced lesions at the left ethmoid sinus.   
(B) There are a few small lymph nodes over the left neck, in other words, this means regression of left 
neck lymphadenopathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. (A) There is still some enhancement at the left ethmoid sinus on Gd-enhanced T1 weighted image.   
(B) The post contrast T1 weighted coronal image shows no abnormal neck lymph node 
 
 
noma or lymphoma in our case. The typical IHC 
statins of ONB were usually positive for NSE and 
synaptophysin [6]. However, the IHC stains were pos-
itive for synaptophysinbut negative NSE in our case 
(Figure 4B, 4C). Although the patient’s MRI produced 
a negative NSE result, it showed typical findings of  
A B
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Figure 4. (A) Small blue round cells were noted in 
HE stain. (B) The neoplastic cells are neg-
ative for NSE. (C) The neoplastic cells are 
positive for synaptophysin 
 
 
ONB, a “dumbbell-shaped” mass across the cribriform 
plate. Therefore, the patient was diagnosed as having 
ONB. 
Generally, the treatment of ONB is surgery, fol-
lowed by radiotherapy if needed [3-5,7]. The SEER 
database (The Surveillance, Epidemiology, and End 
Results Program of the National Cancer Institute) 
analysis included a total of 511 patients with ONB 
from 1973 to 2006. The best management of this trou-
bling disease is surgery with radiotherapy [7]. How-
ever, chemotherapymay also be used for neoadjuvant 
treatment, recurrence or distant metastases. 
Eduardo et al. conducted a study which reviewed 
thirty patients treated for ONB in the M. D. Anderson 
Cancer Center between 1979 and 2002 [8]. Overall 
survival rates at 5 and 10 years post surgery were 89% 
and 81%, respectively. The overall relapse-free sur-
vival rates at 5 and 10 years were 69% and 83%, re-
spectively. For Kadish stage C patients, the 5-year and 
10-year survival rates were 88% and 75%, respective-
ly. Additionally, the relapse-free survival rate for pa-
tients at 5 and 10 years was 61% and 0%, respectively. 
It would appear that Kadish staging was indeed prog-
nostic for survival and recurrence. However, metasta-
sis from ONB portends a poor prognosis. The 5-year 
survival rate of patients with cervical metastasis has 
been reported to be 0% [9]. 
Kiyotaka et al. reviewed 12 patients with ONB 
having unresectable or recurrent disease who received 
chemotherapy at one institution in Japan [10]. Eight of 
the 12 patients received cisplatin-based chemotherapy. 
Three patients received chemotherapy consisting of 
docetaxel plus irinotecan and one received cyclo-
phosphamide, doxorubicin, and vincristine. The over-
all response rate was 42% (5 patients), and the 
chemotherapeutic regimens were heterogeneous. Six 
of the 12 patients did not manifest change in disease 
after chemotherapy. Seven of the 12 patients with only 
loco-regional disease received local adjuvant therapy 
after chemotherapy. Two of these seven patients un-
derwent surgical resection and five received radio-
therapy, including proton–photon therapy. After local 
adjuvant therapy was concluded, a complete response 
was achieved in five patients, and one patient had a 
A 
B 
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partial response. This study showed that olfactory 
neuroblastoma would be sensitive to chemotherapy. 
Kim et al. evaluated neoadjuvant chemotherapy in 
patients with newly diagnosed ONB [11]. A total of 11 
patients were analyzed, and all of them were con-
firmed to be Kadish stage B or stage C disease. The 11 
subjects received chemotherapy with the combination 
of etoposide, ifosfamide, and cisplatin (VIP). This 
regimen led to objective responses in 9 of the 11 pa-
tients (response rate, 82%). Four of these 9 patients 
received radiotherapy after chemotherapy; three of 
these patients who subsequently received radiotherapy 
saw a complete response with the treatment. Overall, 
this study indicated that ONB was highly sensitive to 
chemotherapy and radiotherapy. However, it appears 
that chemotherapy alone is not a curative treatment 
modality due to poor survival rate in the overall pa-
tient group (median survival, 18 months). But, the 
survival rate improved in patients who underwent 
chemotherapy followed by radiotherapy. 
Turano et al. reported a case of ONB with ad-
vanced, stage C progression [12]. The patient was ini-
tially treated by chemotherapy using cisplatin and 
etoposide, alternating cycles with doxorubicin, 
ifosfamide, and vincristine every 21- daycycle. After 
the first cycle, the patient’s symptoms significantly 
improved. Encouragingly, image study after four cy-
cles of chemotherapy showed dramatic remission. The 
patient continued chemotherapy, which was then fol-
lowed by radiotherapy. The patient was still in remis-
sion after 24 months. We modified this regimen to 
include doxorubicin, ifosfamide, and vincristine every 
21- day cycle. The tumor showed good response to the 
chemotherapy. Treatment toxicity included grade 1 
nausea and grade 3 neutropenia. 
Recent reviews suggest that cervical metastasis is 
usually related to distant metastases and poor progno-
sis [9,13]. Therefore, the majority of recent studies 
support the proposition that neck metastasis should be 
treated by neck dissection and radiotherapy [14]. 
However, our case had a very positive response to 
chemotherapy and radiotherapy. No abnormal neck 
lymph node was seen in the MRI after treatment, 
which was the primary reason why the patient did not 
receive surgical intervention. Although we have ob-
served a good response to chemotherapy followed by 
radiotherapy, neck metastases indicated poor progno-
sis, we should keep active surveillance for recurrence 
and distant metastases.  
In conclusion, ONB is a rare tumor originating in 
the nasal cavity. The best way to manage this disease 
is surgical intervention followed by radiotherapy. The 
use of chemotherapy is generally reserved for cases 
involving recurrence and distant metastases. We pre-
sented a case of ONB with cervical metastases, which 
was treated by chemotherapy followed by concurrent 
chemoradiation. A great response was observed after 
treatment without surgery. Such a response indicated 
that ONB is highly sensitive to chemotherapy and ra-
diotherapy. However, cervical metastasis is usually 
related to poor prognosis, and active surveillance re-
mains necessary to give patients the optimum chance 
of extended survival duration. 
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